Skip to main content
Premium Trial:

Request an Annual Quote

SQI's Q2 Revenues Drop to Zero

NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI Diagnostics today reported zero revenues for its fiscal second quarter.

For the three months ended March 31, revenues compare dto the year-ago figure of C$8,000 (US$7,792), the Toronto-based company said in a document filed with Canadian regulators. The results follow first-quarter revenues of C$3,000.

Net loss for the quarter was C$1.4 million, or C$0.03 per share, compared to a net loss of C$1.4 million, or C$0.04 per share, a year ago.

R&D costs were trimmed 3 percent to C$765,000 from C$791,000 in the second quarter of 2012. SG&A costs of C$589,000 during the recently completed quarter were up 4 percent from C$567,000 a year ago.

The firm finished the quarter with C$573,000 in cash and cash equivalents. Earlier this month, SQI closed on a C$3.85 million private placement.

Late last year, it announced the creation of a special committee to review strategic alternatives for the firm, including a possible merger or sale.

"SQI made significant progress in generating customer interest in its diagnostic tools and services offerings during the quarter through a variety of sales and marketing initiatives and that leverages our current IVD technologies," Andrew Morris, SQI's CFO said in a statement today. "We believe that our large pharma sales strategy has created a large pipeline of prospects for evaluation of our technology platforms that we believe will subsequently generate sales for the diagnostic tools and services business this year."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.